PSA密度在血清PSA〈10ng／ml时的鉴别诊断意义

对14例血清前列腺特异性抗原（PSA）值＞10ng／ml的良性前列腺增生症（BPH）患者（BPH组）及12例前列腺癌（PC）患者（PC组）进行了术前PSA及前列腺特异性抗原密度（DPSA）测定。结果BPH织PSA值为29.61±15．89ng／ml，DPSA值为0．60±0．36；PC组PSA值为85．89±53．76ng／ml，DPSA值为1．93±1．31，两组间PSA及DPSA。均有统计学差异（P＜0．002）。认为当血清PSA力10ng／ml时．PSA几乎不能区分BPH和PC，而DPSA以0．7为标准值时，其诊断价值则明显优于PSA。同时分析厂造成BPH者PSA值＞10ng／ml的可能原因。     

良性前列腺增生患者血清PSA与年龄变化的关系

目的　建立我国良性前列腺增生 (BPH)患者血清总前列腺特异性抗原 (T PSA)各年龄段特异性的参考范围。　方法　对 913例年龄 30～ 89岁、初诊为BPH或可疑为前列腺癌 (PCa)的患者行血清T PSA及游离PSA(F PSA)检查。患者均行B超检查 ,对可疑PCa者经直肠超声引导下行前列腺系统穿刺活检。采用单因素回归分析及动态序列分析方法分析患者T PSA、F PSA及F/T比值与年龄变化的关系。　结果　 10 3例患者经活检诊断为PCa ,检出率 11.3%。 810例BPH患者血T PSA及F PSA与年龄呈正相关 (r=0 .2 2 ,P <0 .0 0 1;r =0 .17,P <0 .0 0 1) ,F/T比值与年龄呈负相关 (r = 0 .16 ,P <0 .0 0 1)。T PSA及F PSA每年分别增加约 4 .4 %和 2 .7% ,F/T比值每年下降约1.3%。BPH患者年龄特异性T PSA值 4 0岁～为 0～ 1.5ng/ml;5 0岁～为 0～ 3.0ng/ml;6 0岁～为0～ 4 .5ng/ml;70岁～为 0～ 5 .5ng/ml;80岁～为 0～ 8.0ng/ml。 　结论　BPH患者血清T PSA和F PSA水平与年龄呈正相关 ,而F/T比值与年龄呈负相关 ;建立年龄特异性的T PSA界值范围可以提高PSA诊断PCa的特异性和敏感性     

良性前列腺增生与前列腺癌患者血清总PSA水平与游离PSA比值的比较

目的　探讨血清总前列腺特异性抗原 (T PSA)水平及游离PSA比值 (F/T)在良性前列腺增生 (BPH)与前列腺癌 (PCa)鉴别诊断中的作用。　方法　对 10 3例PCa患者及 810例BPH患者T PSA及F/T值的差异进行分析比较。　结果　BPH患者血清T PSA <4、4～及 >10ng/ml者分别占 71.7%、2 2 .1%、6 .2 % ,PCa患者分别为 10 .7%、17.5 %和 71.8% ,两组间差别有极显著性意义 (P<0 .0 0 5 )。当F/T值 <0 .16时 ,两组患者血清T PSA <4及 4～ 10ng/ml的例数差别有极显著性意义 (P <0 .0 0 5 ) ;但T PSA >10ng/ml的患者 ,两组间差别无显著性意义 (0 .1

10ng/ml时 ,F/T值则无明显鉴别意义     

上海市BPH人群中PSA的年龄特异性分布

目的：建立上海市BPH人群的血清总前列腺特异抗原（T-PSA）的各年龄段特异性的参考值范围。方法：收集2006年12月-2008年4月上海交通大学附属第一人民医院BPH及可疑前列腺癌的4185例上海患者的血清T—PSA值及游离PSA（F—PSA）值。所有患者均有国际前列腺症状评分（I-PSS）、B超检查及直肠指诊。采用单因素直线回归分析方法分析患者T—PSA、F-PSA及F／T比值与年龄的关系。结果：4110例BPH患者血清T—PSA及F-PSA与年龄呈正相关（r=0．28,P〈0．0001及r=0．28,Pd0．0001）,F／T比值与年龄呈负相关（r=-0．05,P=0．0005）;上海市人群T—PSA值的年龄特异性分布大致为：40～49岁者为0～2．2ng／ml,50～59岁者为O～3．4ng／ml,60～69岁者为0～5．5ng／ml,70～79岁者为O～6．7ng／ml,80～89岁者为O～8．4ng／ml,90～99岁者为0～9．4ng／ml。上海市BPH人群较北京市BPH人群各年龄段特异性T-PSA值高,差异有显著统计学意义（t=4．63,P=0．01）;较西安市健康人群高,差异有显著统计学意义（t=3．42,P=0．04）;较黑人社区人群低,差异有显著统计学意义（t=-0．62,P=0．0085）。结论：上海市BPH患者血清T—PSA和F-PSA水平与年龄呈正相关,而F／T比值与年龄呈负相关。血清T—PSA的年龄特异性分布有地区及种族差异。     

f/t PSA比值、PSA密度、PSA移行带密度在tPSA灰区前列腺偶发癌诊断中的意义

【摘要】 目的： 探讨血清f/t PSA比值、PSA密度、PSA移行带密度在tPSA位于灰区时前列腺癌诊断中的意义。方法： tPSA位于4～10ng/ml的前列腺增生患者112例,术前经前列腺穿刺活检均证实为前列腺增生,行TURP术后病理证实21例为前列腺偶发癌患者。回顾性分析该21例前列腺偶发癌患者和其余前列腺增生患者间的血清f/t PSA比值、PSA密度、PSA移行带密度,并进行统计学分析,以了解其在tPSA灰区前列腺偶发癌诊断中的意义。结果：前列腺偶发癌组和BPH组血清f/t PSA比值分别为0.13±0.03、0.21±0.04;PSAD分别为0.20±0.05 ng/ml2 、0.12±0.04 ng/ml2;PSATZ分别为0.38±0.06 ng/ml2 、 0.21±0.05 ng/ml2;两组在以上三个检测指标上差异具有显著性(P<0.05)。以0.15 ng/ml2为截断点则PSAD 灵敏性为76.115%,特异性为69.146%;以0.35 ng/ml2为截断点则PSATZ 灵敏性为60.642%,特异性为93.943%。结论：f/t PSA比值、PSAD、PSATZ对前列腺偶发癌的诊断具有重要价值,其中尤以PSATZ更具预测价值。     

血清游离态前列腺特异抗原水平在前列腺疾病诊断中的应用价值

目的：探讨血清游离态前列腺特异抗原(F—PSA)和总PSA(T—PSA)及F—PSA／T—PSA比值(F／T比值)在前列腺疾病诊断中的应用价值。方法：采用ELISA方法测定30例良性前列腺增生(BPH)患者和45例前列腺癌(PCa)患者血清F—PSA和T—PSA水平，并计算F／T比值。结果：BPH与PCa组患者T—PSA、F—PSA值经t检验差异有显著性意义(P＜0．05)，其F／T比值差异有极显著性意义(P＜0．01)，在PCa的诊断灰区(T—PSA值4.0—10．0μg/L)中，F—PSA及F／T比值能有效区分BPH与PCa(P＜0.05)，单独以T—PSA或F—PSA作为PCa的诊断指标，其敏感度虽高(88．89％，84.44％)，但其特异性较低(仅为53.33％，56．67％)，而以F／T比值作为PCa的诊断指标，在保持较高敏感度的同时，其特异性也可显著提高(P＜0．05)。结论：F—PSA及F／T比值的引入，使PSA作为PCa的诊断指标更为有效，尤其在PCa的诊断灰区，同时F／T比值可显著提高PSA对PCa诊断的特异性。     

血清游离PSA百分率在前列腺癌诊断盲区的价值评价

目的 探讨血清游离前列腺特异性抗原（prostate specific antigen，PSA）百分率在血清总PSA（totalPSA，t—PSA）介于4．0—20．0ng／mL时对前列腺癌（prostate cancer，Pca）的诊断价值。方法用化学发光法测定94例t-PSA介于4．0-20．0ng／mL的未治前列腺疾病患者血清游离PSA（free PSA，f-PSA），其中良性前列腺增生（benign prostatic hyperplasia，BPH）患者77例，Pca患者17例，并计算其f-PSA百分率（f／t-PSA）。结果 t-PSA介于4．0-20．0ng／mL时，Pca组f／t—PSA明显低于BPH组（P〈0.01）。以f／t—PSA为0．18、0．22为界值时其诊断Pca的敏感度为83．9％、94．1％，特异度为75．2％、63．7％，阳性预测值为42．5％、37．1％，阴性预测值为95．4％、98．3％。结论 t-PSA介于4．0-20．0ng／mL诊断盲区时，f／t-PSA对诊断Pca有较好的临床价值，以0．22为界值其敏感度达94．1％，阴性预测值达98．3％。     

前列腺癌、前列腺增生症患者血清骨保护素测定的临床价值

目的探讨前列腺癌（PCa）患者和前列腺增生（BPH）症患者血清中骨保护素（OPG）浓度的差异以及前列腺癌患者骨保护素浓度与血清前列腺特异性抗原（PSA）水平、前列腺体积是否具有相关性。方法采用双抗体夹心酶免法（ELISA）测定40例前列腺癌患者及40例前列腺增生患者血清OPG浓度,同时采集PCa患者的前列腺体积及PSA值。比较PCa患者及BPH患者血清OPG浓度的差异以及前列腺癌患者中OPG浓度与PSA、前列腺体积之间有无相关性。结果 PCa患者的血清OPG浓度平均值水平〔（14 900.19±5 168.65）pg/mL〕显著高于BPH组〔（10 457.87±4 786.29）pg/mL〕,差异有显著性意义（P〈0.01）。PCa患者血清OPG浓度与PSA值及前列腺体积之间均无明显相关性（r分别为=0.221、0.138,P均〉0.1）。结论血清OPG浓度对鉴别PCa和BPH有重要临床价值,PCa患者血清OPG浓度与血清PSA值及前列腺体积无明显相关性。     

f-PSA/t-PSA比值在良性前列腺增生和前列腺癌鉴别诊断中的应用

目的：探讨血清总前列腺特异性抗原（t-PSA）及游离前列腺特异性抗原（f-PSA）在BPH和PCa患者中的表达，评价t-PSA与f-PSA／tPSA在BPH和PCa鉴别诊断中的应用价值。方法：对经直肠超声引导下前列腺穿刺活检诊断为BPH和PCa的患者，结合其术前的t-PSA及f-PSA检测结果，进行回顾性分析和统计。结果：在t—PSA％4．0μg／L的患者中，f-PSA／t—PSA〈0．16者共6例（BPH3例；PCa 3例），〉0．16者共20例（BPH13例；PCa例7）；4．0≤t—PsA〈10．0μg／L的患者中，f-PSA／t—PSA〈0．16者共17例（BPH5例；PCa 12例），〉0．16者共24例（BPH21例；PCa3例）；10．0≤t—PSA〈100μg／L的患者中，f-PSA／t-PSA〈0．16者共49例（BPH19例；PCa30例），〉0．16者共31例（BPH22例；PCa9例）；t—PSA≥100μg／L的患者16例，均为PCa，f-PSA／t—PSA比值均〈0．16。结论：BPH患者随年龄增长t—PSA逐渐升高，但f-PsA／t—PSA值差异无统计学意义（P〉0．05），而不同年龄的PCa患者t-PSA、f-PSA及f-PSA／t-PSA值均差异无统计学意义（P〉0．05）；t-PSA水平在4．0～10．0ug／L的PCa患者和t—PSA在10～100μg／L的PCa患者相比，其f-PSA／t—PSA比值差异无统计学意义（P〉0．05）；对于4．0≤t—PSA〈10．0的患者，结合f-PSA／t-PSA〈0．16，能更有效地区别BPH和PCa（P〈0．05），但是，对于t—PSA％4．0μg／L的PCa患者来说，f-PSA/t-PSA比值对其与BPH的鉴别意义不大（P〉0．05）。     

前列腺癌内分泌治疗对血PSA的影响及其临床意义

目的探讨进展期前列腺癌（PCa）患者内分泌治疗前后前列腺特异性抗原（PSA）变化的临床意义。方法测定PCa患者内分泌治疗前和治疗后3、6、12、24个月血清PSA。结果治疗后3个月与治疗前相比血清PSA下降明显。治疗后6个月达到PSA谷值。结论血清PSA可作为判断PCa内分泌治疗效果的标准，血清PSA再次升高（〉4ng／ml）提示肿瘤发展为非激素依赖性前列腺癌，是预测生存率的一个独立因素。     

IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging

PURPOSE: IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of PCa. METHODS: 112 patients who underwent surgery for BPH or PCa (no hormonal treatment, no further malignancies) were included in this study ((I) 38 PCa, PSA < or = 15 ng/ml; (II) 34 PCa, PSA > 15 ng/ml; (III) 40 BPH). Preoperative serum levels of total PSA and total IGF-II were determined by ELFA and ELISA, respectively. RESULTS: PSA levels were (I) 5.7+/-1.9 ng/ml; (II) 25.0+/-11.5 ng/ml and (III) 4.0+/-2.8 ng/ml. (II) was statistically associated with a high grading (2b/3; p = 0.0182), a high Gleason sum score (7-10; p = 0.0049) and a non-organ confined tumor (T3/4; p = 0.0009) compared to (I), all Chi2 test. IGF-II levels were significantly higher in PCa (I+II) compared to BPH (833.8+/-238.9 ng/ml vs. 633.3+/-141.4 ng/ml, p < 0.0001, t-test). Both PSA and IGF-II were associated with tumor staging (p = 0.0097, p = 0.0308; t-test). No significant correlation was observed between PSA and IGF-II levels. Logistic regression analysis revealed that the combination of PSA and IGF-II improves the prediction of tumor staging in PCa (p = 0.0175 and p = 0.0459, Wald test). Additionally, the combination of PSA and IGF-II can significantly increase discrimination between BPH and PCa; each p < 0.0001, Wald test. CONCLUSIONS: This study provides evidence that IGF-II serum levels may serve as an additional parameter for (a) improved determination of tumor staging and (b) better discrimination between BPH and PCa.     

Effect of NIH-IV prostatitis on free and free-to-total PSA

OBJECTIVE: To examine the effect of asymptomatic prostatic inflammation (NIH category IV prostatitis) on total PSA (tPSA), free serum PSA (fPSA) and the ratio of free-to-total prostate specific antigen (%fPSA). The role of free and %fPSA as a diagnostic tool for distinguishing between cancer and non-malignant diseases of the prostate was also investigated. MATERIAL AND METHODS: In a retrospective study 1090 prostate biopsies performed between January 2000 and September 2003 were evaluated and the levels of serum total and free PSA as well as the f/tPSA ratio were determined in samples obtained immediately before biopsy. 404 patients with full clinical and histological records were included in the study. All patients underwent 6 or 8 core primary prostate needle biopsies. RESULTS: A total of 404 patients were included in the analysis. 100 prostate cancer (PCa) (24.8%), 137 NIH-IV prostatitis (33.9%) and 143 patients with benign prostatic hyperplasias (BPH) (35.4%) were identified. 24 (5.9%) patients presented with both PCa and prostatitis on histology and were excluded from further analysis. The mean (median) levels of tPSA, fPSA and %fPSA were 11.94 ng/ml (8.0), 1.31 ng/ml (1.07) and 0.15 (0.14) for NIH-IV prostatitis; 11.94 ng/ml (8.35), 1.54 ng/ml and 0.13 (0.11) for prostate cancer; and 8.19 ng/ml (7.0), 1.48 ng/ml (1.03) and 0.18 (0.15) for BPH. No significant difference was found in tPSA levels between PCa and prostatitis (p = 0.32), while the difference in tPSA levels between PCa and BPH was significant (p = 0.007). Free PSA alone had no diagnostic power in distinguishing PCa from prostatitis (p = 0. 37) and BPH (p = 0. 61). By contrast, the f/tPSA ratio showed significant between-group differences (PCa versus prostatitis (p = 0. 011), PCa versus BPH (p = 0.0001). CONCLUSIONS: Chronic asymptomatic prostatitis NIH category IV has similar effects on total PSA and free PSA levels in serum as PCa. fPSA alone cannot distinguish prostate cancer from non-malignant inflammatory disease of the prostate. The ratio of free-to-total PSA is significantly different in PCa and NIH category IV prostatitis.     

Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer

BACKGROUND: We investigated the clinical usefulness of free to total serum prostate specific antigen (PSA) ratio (F/T ratio) in order to improve the specificity of total PSA measurement for detecting prostate cancer. METHOD: In this study 129 patients with total PSA level 4-20 ng/ml underwent transrectal ultrasound guided sextant biopsy. Serum samples were assessed for total PSA, free PSA and the F/T ratio calculated. All patients were pathologically diagnosed as benign prostatic hyperplasia or prostate cancer. RESULTS: Of 129 patients 21 had prostate carcinoma (PCa) and 108 had benign prostatic hyperplasia (BPH) from the results of prostate biopsies. The mean of total PSA were not significantly different between men with PCa and with BPH. The mean of free PSA for PCa was significantly lower than that for BPH (p = 0.043). Furthermore, the mean of F/T ratio was significantly different between PCa and BPH group (p = 0.0014). The F/T ratio had a higher specificity than total PSA at all levels of sensitivity in detecting prostate cancers. Sensitivity, specificity and accuracy for cancer detection at a cut off 0.12 was 90.4%, 51.8% and 58.1%, respectively. Also, free PSA was as useful as F/T ratio for cancer detection when analyzed in receiver operating characteristic curves analysis. When determined the cut off number of free PSA at 0.78 ng/ml, the sensitivity, specificity and accuracy for cancer detection were 61.9%, 66.7% and 65.9%, respectively. CONCLUSION: This study indicated that the F/T ratio and free PSA could improve the specificity without impairing the sensitivity for detecting PCa in patients with 4-20 ng/ml of total PSA.     

Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer

BACKGROUND: To compare the clinical value of the measurement of complex and total PSA in the discrimination between benign prostatic hyperplasia (BPH) and prostate cancer. METHODS: In serum samples collected from 166 men with histopathologically proven clinically localized prostate cancer and of 97 men with BPH, total prostate-specific antigen (PSA), complexed PSA and the free to total PSA ratio were determined. The statistical analysis was done by the comparison of the receiver operator characteristic (ROC) curves. RESULTS: The areas under the ROC curves were 0.776 for total PSA, 0.799 for complexed PSA (total PSA vs. cPSA: p < 0.0001) and 0.812 for the free to total PSA ratio. With a cut-off of 3.0 ng/ml for complexed PSA, the sensitivity was 90%, the specificity 58%, the positive and the negative predictive values 79 and 78%, respectively. With a cut-off of 4.0 ng/ml for total PSA, the sensitivity was 87%, the specificity 59%, the positive and the negative predictive values were 78 and 72%, respectively. CONCLUSIONS: There was a statistically significant advantage for complexed PSA compared to total PSA in the discrimination between BPH and prostate cancer. The difference was, however, small and its clinical relevance is questionable.     

诊断性前列腺电切术对血清PSA异常患者的应用研究

目的:探讨诊断性前列腺电切(TURP)在前列腺增生合并血清PSA异常患者中的应用价值及意义,为临床处理前列腺增生合并血清PSA异常的患者提供一种新的手段。方法:收集符合入组标准的患者71例,总结病理为前列腺癌患者的Gleason评分及预后。对所有患者进行术后随访,检测其TURP术后6个月、1年的PSA值及IPSS评分,分析术后血清PSA值、IPSS的变化,评估TURP在前列腺增生伴血清PSA异常患者中的诊疗效果。结果:①40例前列腺穿刺活检阴性而血清PSA持续异常的患者中,2例术后病理示前列腺腺癌(2/40),Gleason评分为6分,另1例电切后病理示前列腺增生组织,但术后血清PSA持续异常(18μg/L),行2次活检,病理诊断为前列腺癌,Gleason评分6分,3例均行前列腺根治性切除术,术后随访恢复好。31例拒绝活检患者中术后病理示前列腺腺癌9例(9/31)。Gleason评分7⁹分,平均8分,1例行前列腺根治性切除术,8例行内分泌治疗。②59例病理诊断为良性前列腺增生(BPH),其中血清PSA恢复正常者56例,显著降低者3例,IPSS评分有明显改善53例,6例尿道狭窄经过尿扩处理后评分亦有改善。结论:诊断性TURP可提高前列腺癌的早期检出率,改善患者的下尿路症状,且有利于患者血清PSA持续正常化。对血清PSA异常(>4μg/L),伴有下尿路梗阻状态、前列腺穿刺活检阴性的患者可考虑行诊断性TURP。     

Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

Purpose:

We assessed the role of urinary prostate-specific antigen (uPSA) in the follow-up of prostate cancer after retropubic radical prostatectomy (RRP) for the early detection of local recurrences.

Methods:

We recruited 50 patients previously treated for prostate cancer with RRP and who had not experienced a prostate-specific antigen (PSA) recurrence within their first postoperative year into a cross-sectional laboratory assessment and prospective 6-year longitudinal follow-up study. We defined biochemical failure as a serum PSA (sPSA) of 0.3 μg/L or greater. Patients provided blood samples and a 50-mL sample of first-voided urine. We performed Wilcoxon rank-sum and Fisher exact tests for statistical analysis.

Results:

The median sPSA was 0.13 μg/L. The median uPSA was 0.8 μg/L, and was not significantly different when comparing Gleason scores or pathological stages. Of the 50 patients, 27 initially had a nondetectable sPSA but a detectable uPSA, and 11 patients experienced sPSA failure after 6 years. Six patients had detectable sPSA and uPSA initially. Fifteen patients were negative for both sPSA and uPSA, and 13 remained sPSA-free after 6 years. The odds ratio (OR) of having sPSA failure given a positive uPSA test was 4.5 if sPSA was undetectable, but was reduced to 2.6 if sPSA was detectable. The pooled Mantel–Haenszel OR of 4.2 suggested that a detectable uPSA quadrupled the risk of recurrence, independent of whether sPSA was elevated or not. The sensitivity of uPSA for detecting future sPSA recurrences was 81% and specificity was 45%.

Conclusion:

Urinary PSA could contribute to an early detection of local recurrences of prostate cancer after a radical prostatectomy.     

血清EPCA-2检测在前列腺癌诊断中的临床意义

目的：通过比较血清中早期前列腺癌抗原-2（EPCA-2）与前列腺特异性抗原（PSA）在前列腺癌（PCa）诊断中的特异性与敏感性,研究血清中EPCA-2对诊断PCa的临床意义。方法：收集非前列腺疾病患者20例（作为A组）,BPH患者56例（作为B组）,PCa患者44例（作为C组）,采用酶联免疫吸附实验（ELISA）分别检测三组患者血清中EPCA-2和PSA水平,进行统计学分析。结果：①C组患者血清中EPCA-2和PSA水平分别与A组和B组患者的进行比较,均显著增高,差异有统计学意义（P〈0．01）。②A组血清中EPCA-2水平均≤分界点（30μg／L）。③以30μg／L为分界点,EPCA-2对PCa诊断的特异性为92．1％,敏感性为93．2％;以4μg／L为分界点,PSA对PCa诊断的特异性为55．3％,敏感性为79．5％;PSA结合fPSA／tPSA（以0．15为分界点）,对PCa诊断的特异性为78．9％,敏感性为68．2％。结论：EPCA-2作为新的诊断PCa的肿瘤标志物,较PSA具有更高的特异性和敏感性,对临床PCa的诊断具有重要意义。     

TURP对BPH患者血清PSA水平的影响

目的:通过经尿道前列腺电切术(TURP)的BPH患者血清前列腺特异抗原(PSA)的近、远期变化,探讨TURP前后PSA变化的价值及PSA变化与切除程度的相关性。方法:前瞻性队列研究209例接受TURP的BPH患者术前、术后5天、术后1个月、术后3个月、术后半年的血清PSA水平变化及PSA变化与切除程度的相关性。结果:术前PSA水平为(9.82±9.60)μg/L,术后5天为(5.40±4.04)μg/L,术后1个月为(3.5±3.15)μg/L,术后3个月为(2.56±1.13)μg/L,术后半年为(3.47±1.04)μg/L。术后5天与术前相比,PSA下降约(4.42±8.78)μg/L,术后1个月降至术前的35%,5段时间PSA水平互相对比,差异均有统计学意义(P0.01)。PSA4μg/L组PSA下降后仍高于PSA≤4μg/L组。TURP的实际切除质量与应该切除质量相减的均数±标准差,总样本为(-0.941±9.56)μg/L,PSA≤4μg/L组为(0.13±10.53)μg/L,PSA4μg/L组为(-3.83±5.41)μg/L。PSA的变化与切除程度呈正相关(P0.01,R=0.91),并且PSA≤4μg/L组与PSA4μg/L组PSA的变化均与切除程度呈正相关(P0.01,1=0.986,R2=0.924),两组间差别无统计学意义。结论:PSA在TURP后呈下降趋势,于1个月左右降至正常水平,并且TURP切除的范围越足够,PSA下降的幅度越大。术后长期随访BPH患者TURP后血清PSA水平,能减少前列腺癌的误诊及漏诊。对于监测术前PSA4μg/L的BPH患者应以其术后自身PSA基线为准,衡量其前列腺穿刺活检的指征及前列腺癌的诊断。     

＂诊断性＂TURP在BPH伴血清PSA异常患者中的应用价值

目的：探讨“诊断性”TURP在BPH伴血清PSA异常患者中的应用价值及意义。方法：对BPH伴血清PSA异常患者行“诊断性”TURP,然后对手术切除的前列腺组织行病理检查,按照病理诊断结果分为PCa组和BPH组,分别评估PCa组患者的临床分期及Oleason评分和BPH组患者TURP术后3个月、6个月、1年及随访结束时血清PSA、IPSS评分、生活质量等。结果：87例BPH伴血清PSA异常者行“诊断性”TURP,病理诊断为PCa5例,Gleason评分5～8分,肿瘤分期T1a～T2a,行PCa根治性切除术;病理诊断为BPH82例,出院后均随访2～4年,其中血清PSA恢复正常者77例,显著下降者3例,持续异常者2例,IPSS评分均有明显降低。结论：对血清PSA异常患者,“诊断性”TURP可有助于诊断PCa并对下尿路症状的改善和血清PSA的正常化具重要作用。